Posted by Michael Wonder on 16 Aug 2025
FDA approves first immunotherapy for recurrent respiratory papillomatosis
14 August 2025 - Today, the US FDA approved Papzimeos (zopapogene imadenovec-drba), a first of its kind non-replicating adenoviral vector-based immunotherapy for the treatment of adult patients with recurrent respiratory papillomatosis.
The approval is based on results from a single-arm, open-label trial evaluating Papzimeos in adult patients with recurrent respiratory papillomatosis who required three or more surgeries per year.
